Loading
A phase 2 trial of pembrolizumab and olaparib in pancreatic cancer, run by Cambridge University Hospitals NHS Foundation Trust, now recruiting.
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT05093231 by Cambridge University Hospitals NHS Foundation Trust, with a registry enrolment figure of 20 participants, started 2025-02-26 and due to reach its primary completion in 2027-07-31. Interventions recorded: Pembrolizumab; Olaparib. Conditions listed: Pancreatic Cancer. Primary outcome: Objective Response Rate (ORR). Sites: Australia, United Kingdom. United Kingdom sites listed: 15. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares PARP inhibitors, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares PARP inhibitors, Olaparib, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/